IL-18

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
IL-18 (Human)

GtoPdb Ligand ID: 4983

Synonyms: ibocatdekin | interferon-γ-inducing factor | interleukin-1 gamma (IL-1 gamma) | interleukin-18

Compound class: Endogenous peptide in human, mouse or rat

Comment: IL-18 is an IL-1 family cytokine. It acts as a pleiotropic pro-inflammatory cytokine, and it is important for host innate and adaptive immune defense against pathogenic infections. Dysregulated IL-18 activity is associated with inflammatory and autoimmune diseases (e.g. rheumatoid arthritis, Crohn's disease, MS and lupus), allergies, and neurological disorders. IL-18 and its signalling partners are protein targets for anti-inflammatory drug development.

Species: Human

References
1. Jang YS, Lee K, Park M, Joo Park J, Choi GM, Kim C, Dehkohneh SB, Chi S, Han J, Song MY et al.. (2023) Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation. Cytokine, 172: 156413. [PMID:37918054]
2. Krumm B, Meng X, Xiang Y, Deng J. (2017) Identification of small molecule inhibitors of Interleukin-18. Sci Rep, 7 (1): 483. [PMID:28352119]
3. Park SY, Hisham Y, Shin HM, Yeom SC, Kim S. (2022) Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases. Biomedicines, 10 (7). [PMID:35885055]
4. Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona C et al.. (2015) Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology (Oxford), 54 (8): 1507-17. [PMID:25767156]
5. Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, Kubota T, Yamasaki Y, Takei S, Yachie A. (2015) Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol, 160 (2): 277-81. [PMID:26101092]
6. Yasin S, Schulert GS. (2018) Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment. Curr Opin Rheumatol, 30 (5): 514-520. [PMID:29870499]

References

1. Jang YS, Lee K, Park M, Joo Park J, Choi GM, Kim C, Dehkohneh SB, Chi S, Han J, Song MY et al.. (2023)
Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation.
Cytokine, 172: 156413. [PMID:37918054]

2. Krumm B, Meng X, Xiang Y, Deng J. (2017)
Identification of small molecule inhibitors of Interleukin-18.
Sci Rep, 7 (1): 483. [PMID:28352119]

3. Park SY, Hisham Y, Shin HM, Yeom SC, Kim S. (2022)
Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases.
Biomedicines, 10 (7). [PMID:35885055]

4. Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona C et al.. (2015)
Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
Rheumatology (Oxford), 54 (8): 1507-17. [PMID:25767156]

5. Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, Kubota T, Yamasaki Y, Takei S, Yachie A. (2015)
Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Clin Immunol, 160 (2): 277-81. [PMID:26101092]

6. Yasin S, Schulert GS. (2018)
Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.
Curr Opin Rheumatol, 30 (5): 514-520. [PMID:29870499]